23 Jun 17

Arena, Eisai collaborate in response to FDA’s lorcaserin Complete Response Letter Arena Pharmaceuticals, Inc. and Eisai Inc ?process of cancer spreading . Announced today that Arena offers submitted its response to the Complete Response Letter released by the united states Food and Drug Administration following overview of the lorcaserin New Drug Application . Lorcaserin is intended for weight management, including weight loss and maintenance of fat loss, in individuals who are obese or individuals who are overweight and have at least one weight-related co-morbid condition.

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection Arrowhead Research Corporation , a biopharmaceutical business developing targeted RNAi therapeutics, today announced that it completed enrollment in a Stage 1 clinical trial of ARC-520, its RNAi-based applicant against chronic hepatitis B virus infection. Initial data show that ARC-520 is safe and well tolerated at all six dose levels studied generally, enabling the company to proceed with programs to initiate a Stage 2a pilot efficacy study in chronic HBV sufferers. ‘We are very pleased with these results and the pace at which we could actually complete the Phase 1 study.